title: Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
abstract: Recent studies have described several broadly neutralizing monoclonal antibodies (bN-mAbs) that recognize glycan-dependent epitopes (GDEs) in the HIV-1 envelope protein, gp120. These were recovered from HIV-1 infected subjects, and several (e.g., PG9, PG16, CH01, CH03) target glycans in the first and second variable (V1/V2) domain of gp120. The V1/V2 domain is thought to play an important role in conformational masking, and antibodies to the V1/V2 domain were recently identified as the only immune response that correlated with protection in the RV144 HIV-1 vaccine trial. While the importance of antibodies to polymeric glycans is well established for vaccines targeting bacterial diseases, the importance of antibodies to glycans in vaccines targeting HIV has only recently been recognized. Antibodies to GDEs may be particularly significant in HIV vaccines based on gp120, where 50% of the molecular mass of the envelope protein is contributed by N-linked carbohydrate. However, few studies have reported antibodies to GDEs in humans or animals immunized with candidate HIV-1 vaccines. In this report, we describe the isolation of a mouse mAb, 4B6, after immunization with the extracellular domain of the HIV-1 envelope protein, gp140. Epitope mapping using glycopeptide fragments and in vitro mutagenesis showed that binding of this antibody depends on N-linked glycosylation at asparagine N130 (HXB2 numbering) in the gp120 V1/V2 domain. Our results demonstrate that, in addition to natural HIV-1 infection, immunization with recombinant proteins can elicit antibodies to the GDEs in the V1/V2 domain of gp120. Although little is known regarding conditions that favor antibody responses to GDEs, our studies demonstrate that these antibodies can arise from a short-term immunization regimen. Our results suggest that antibodies to GDEs are more common than previously suspected, and that further analysis of antibody responses to the HIV-1 envelope protein will lead to the discovery of additional antibodies to GDEs.
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Rachel C
authors.initials: RC
authors.lastname: Doran
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Javier F
authors.initials: JF
authors.lastname: Morales
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Briana
authors.initials: B
authors.lastname: To
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Trevor J
authors.initials: TJ
authors.lastname: Morin
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Richard
authors.initials: R
authors.lastname: Theolis
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Sara M
authors.initials: SM
authors.lastname: O'Rourke
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Bin
authors.initials: B
authors.lastname: Yu
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Mesa
authors.affiliation: Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, United States of America.
authors.forename: Phillip W
authors.initials: PW
authors.lastname: Berman
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology / Q000302:isolation & purification; D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000302:isolation & purification; D002478:Cells, Cultured; D018604:Epitope Mapping; D000939:Epitopes / Q000737:chemistry / Q000276:immunology*; D057809:HEK293 Cells; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D011134:Polysaccharides / Q000276:immunology*; D017434:Protein Structure, Tertiary
chemical_list: D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000939:Epitopes; D015699:HIV Envelope Protein gp120; D011134:Polysaccharides
keywords: Epitope; Glycosylation; Gp120; HIV; Monoclonal antibody; V1/V2 domain